Bluprint Oncology’s Post

Abemaciclib, a targeted therapy for breast cancer, is emerging as the most dynamic molecule in the market. With its impressive efficacy, favorable side effect profile, and relatively simple regimen, it's paving the way for future treatments. This #BreastCancerAwarenessMonth, we acknowledge the significance of such advancements and reaffirm our commitment to providing the highest quality APIs for breast cancer management. Contact us for more details. API@polpharma.com CDMO@polpharma.com Product under Polpharma API - Egis Pharmaceuticals PLC cooperation #HPAPI #BreastCancerAwarenessMonth #oncology

NEW from #ASCO2024 | The ABCs of ADCs: what does the future hold? 🎥 🇺🇸 Erika Hamilton, MD, Sarah Cannon Research Institute, delves into the future of #antibodydrugconjugates (#ADCs) in #oncology, encompasses insights from various #disease types, including #myeloma, #lungcancer, and #breastcancer 🩸 🫁 🌟 Dr Hamilton highlights the evolution of #ADCs over the past two decades, emphasizing their expansion beyond highly expressing targets to include #antigens with lower expression levels 🌟 She discusses the promising development of ADCs targeting novel antigens, such as TROP-2, and explores innovative strategies like payload masking and #bispecific targeting to overcome resistance and enhance tolerability 🌟 Dr Hamilton envisions #ADCs revolutionizing #oncologycare and underscores the importance of understanding #antigenexpression and optimizing drug #sequencing in future #research and #clinicalpractice 🔦 Learn more 👉 https://lnkd.in/e2ZN-b8r #VJOncology #Oncologynews American Society of Clinical Oncology (ASCO)

Oncology clinical trials are on the rise! Two trends are emerging in cancer treatment: the development of cancer-targeting drugs and the influx of biomarkers. Each oncology trial presents unique challenges, from multifaceted study protocols to diverse sample types. In this article, we will dive into the complexities of early oncology clinical trials, with a specific focus on sample management. Read article 👉 https://lnkd.in/eQMrJ65b #healthscience #cancerresearch #oncology

BioMed X Institute Launches New Collaboration with Daiichi Sankyo in Cancer Therapy. New partnership to advance the development of bi- and multi-specific biologics for treating solid tumors https://lnkd.in/e8aTNZe5 #biotech #oncology BioMed X Institute

🔬 Sun Pharma Advanced Research Company Ltd. (SPARC) has teamed up with UCSF and Tiller Therapeutics to advance a promising pre-clinical oncology asset, aimed at addressing solid tumors with no current cure. 🌍 This collaboration could significantly impact the future of cancer treatment. Learn more about the terms of this groundbreaking partnership and what’s next for cancer research. 👉 Click the link to read more: https://lnkd.in/gYChjrek #CancerResearch #Oncology #PharmaPartnership #SPARC #UniversityofCalifornia

⏰ Don’t miss your chance to enroll in the Champions' Gastric Cancer TumorGraft3D screening—closing in just two weeks! Enroll Today: https://hubs.li/Q02Nwgds0 🌟 Enroll by September 18 to test the efficacy of your gastric cancer therapeutics on our state-of-the-art ex vivo platform featuring models derived from a diverse collection of rare and extensively characterized 3D organoids, sourced from low-passaged PDX models. These models offer an authentic representation of patient tumor heterogeneity and are assessed using a unique matrix-free assay with proprietary media. #cancertherapeutics #exvivo #3Dtumormodels #PDX #cancerresearch #gastriccancer #Drugdevelopment #drugscreening #Oncology #translationalresearch #preclinicaloncology

Today, we honor World Breast Cancer Research Day which was founded in 2021. We acknowledge the progress made and recognize the journey continues until there is a cure for breast cancer. According to the website, https://lnkd.in/gmz9CrZ, 1 in 8 women and 1 in 833 men will be diagnosed with breast cancer in their lifetimes. Let’s continue to support and advocate for breakthroughs in breast cancer research. Together, we can make a difference. #ImaginAb #CD8ImmunoPET #RPT #biotech #theranostics #immunoonocology  #research #clinicaltrials #BreastCancerResearch #Pharmaceuticals #WorldBreastCancerResearchDay

🎯 DLL3 ADC: A Breakthrough in Oncology! 🎯 Innovative Antibody-Drug Conjugates (ADCs) targeting DLL3 are paving the way for transformative cancer therapies. 🧬 These advancements offer new hope in the fight against aggressive tumors. 🚀💉 IDEAYA Biosciences Hengrui Pharma Co.,Ltd Know complete story - https://lnkd.in/d4uCP2eD #CancerInnovation #OncologyBreakthrough #DLL3ADC #PharmaAdvancements #PatientCare

The countdown for the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting is on and we're excited to meet you in Chicago. Schedule a meeting with our team to discover how our AI-driven spatial biomarkers are advancing next-gen cancer treatments, like bi-specifics, ADCs, and immunotherapies.—because next-gen oncology treatments need next-gen biomarkers! https://bit.ly/3UFaMwY #ASCO24, #biomarkers #spatialbiomarkers #CDx #SpatialBiology #PrecisionOncology #PrecisionMedicine #DigitalPathology #ClinicalTrials #Oncology

Can bispecific ADCs be the future of targeted cancer therapy? 🎯 Antibody-drug conjugates (ADCs) have transformed oncology, but balancing effectiveness with off-target toxicity remains a challenge. Enter bispecific ADCs – a promising next-gen approach that aims to improve tumor targeting and address tumor heterogeneity. With multiple early-stage trials underway and significant dealmaking, this space is heating up. 🔥 This week, we dive into the potential of bispecific ADCs with Radek Spisek, CEO of SOTIO Biotech. 🎤 Listen now!  🎧 https://lnkd.in/dSPa8FzW #BeyondBiotechPodcast #BispecificADCs #cancertherapy #targetedtherapies #oncologyinnovation #ADCtechnology #cancerresearch